Pedro Valencia, VP, asset strategy leadership, oncology, outlines how unmet need, treatment stagnation, and pipeline innovation shape the company’s approach to solid tumor oncology following key data ...

AbbVie said on Monday its treatment for a group of blood cancers failed to meet the main goal of significantly improving the ...

(Reuters) -AbbVie said on Wednesday its migraine drug met the main goal and was superior to a widely used generic treatment ...

AbbVie is deploying more capital into its pipeline, which features 50 programs in mid- and late-stage development and over ...

AbbVie's Phase 3 VERONA trial in HR-MDS showed no overall survival benefit for venetoclax-azacitidine; existing uses of ...

AbbVie Inc. (NYSE:ABBV) is one of the best dividend stocks for a bear market. The company holds the title of a Dividend King, ...

AbbVie combines high yield, strong growth from Rinvoq and Skyrizi, and a solid pipeline to support dividends and returns.

The trial judged the tolerability, safety and efficacy of atogepant, at 60 milligrams once daily, compared to the ...

The AbbVie-Roche cancer drug venetoclax failed to meet its primary endpoint in a phase 3 trial to treat newly diagnosed ...

Antibody drug conjugates, or ADCs, are still holding on to their spot as one of the hottest areas in cancer care—and AbbVie, ...

Roche and AbbVie have come up short again in their effort to gain an additional indication for their blockbuster blood cancer ...

AbbVie said its Phase 3 trial evaluating venetoclax in combination with azacitidine to treat higher-risk myelodysplastic syndrome didn't meet the primary endpoint of overall survival. The drugmaker ...